Xenikos is a pioneering brand focused on resetting the immune system to combat T-cell mediated diseases. They are developing a revolutionary therapy called T-Guard™, which consists of two toxin-loaded anti-T-cell antibodies. With its innovative immunotherapy approach, Xenikos aims to provide a therapeutic tool to reset the body's immune system.

In June 2022, Xenikos initiated a global Phase 3 clinical study to evaluate T-Guard® in patients with grade III/IV steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplant. However, the study was discontinued in early 2023 based on the recommendation of the Data Safety and Monitoring Board (DSMB). Patient safety being their top priority, Xenikos made the difficult decision to cease operations.

Despite this setback, Xenikos is grateful to the patients, families, employees, investors, and partners for their support. The valuable data gathered from this research will contribute to future studies on T-Guard and other devastating diseases. Additionally, there is ongoing exploration of the potential development of T-Guard for different clinical indications.

For more information on T-Guard® and Xenikos, please visit their website. (Address: Xenikos B. V.

Wilhelminasingel 14, 6524 AL Nijmegen, Email: info@xenikos. com)